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INTRODUCTION:  Intra  and  perioperative  anticoagulation  in  patients  with  heparin  induced  thrombocy-
topenia  (HIT),  candidates  for peripheral  vascular  surgery  remains  a challenge,  as  the  best alternative  to
heparin  has  not  yet  been  established.  We  evaluated  the  off-label  use  of  fondaparinux  in four  patients
with HIT,  undergoing  peripheral  vascular  surgery  procedures.
PRESENTATION  OF  CASES:  Four  patients  of  whom  3  men  of  a mean  age  of  66 years,  with  proven  heparin
induced  thrombocytopenia  (HIT) underwent  two  axillo-femoral  bypasses,  one  femoro-popliteal  bypass
and one  resection  of  a splenic  artery  aneurysm  under  fondaparinux.  No  intra  or  perioperative  bleeding
or  thrombosis  of new  onset  was observed.
DISCUSSION:  In the absence  of a valid  alternative  to heparin  for  intra  and  perioperative  anticoagulation
in  HIT,  several  other  anticoagulants  can  be  used  in  an off-label  setting.  However,  no  general  consensus
exist  on which  should  be the one  of  choice.  In  this  small  series  fondaparinux  appeared  to  be  both  safe
and  effective.
CONCLUSIONS:  These  preliminary  results  seem  to justify  the off-label  use  of  fondaparinux  for  intra  and
perioperative  anticoagulation  in patients  with  HIT,  candidates  for peripheral  vascular  surgery  interven-
tions.
© 2016  The  Authors.  Published  by  Elsevier  Ltd  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
The ﬁrst cases of heparin-induced thrombocytopenia (HIT) asso-
iated with arterial and venous thrombosis were reported in 1958
1]. Since then several other observations conﬁrmed the role of
eparin in occasionally inducing thrombocytopenia, arterial and/or
enous thrombosis due to a grayish clot for which the term
white clot” syndrome was also used [2]. Patients with HIT form
mmunoglobulin G and/or immunoglobulin M antibodies against a
omplex of platelet factor 4 (PF 4) and heparin [3]. This thrombo-
ytopenia with white clot formation is also triggered by calciparin
nd low-molecular weight heparins, which, as well as sodium
eparin, are strongly contraindicated in this condition. Heparins
an be fairly easily replaced by other anticoagulants in the cur-
ent medical settings requiring anticoagulation, in case of heparin
nduced thrombocytopenia [4]. On the other hand, replacing hep-
rin for intraoperative anticoagulation in vascular surgery is not
∗ Corresponding author at: Via Vincenzo Bellini 14, 00198 Rome, Italy.
E-mail address: giulio.illuminati@uniroma1.it (G. Illuminati).
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210-2612/© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Gro
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
as simple, since sodium heparin bears the unique advantages of
immediate efﬁcacy, possibility of direct graft and runoff vessels irri-
gation, and immediate action reversal with protamine. No other
anticoagulant has all these same properties and, given the rarity
of this syndrome, the optimal alternative to heparin for intraop-
erative anticoagulation has not yet been established [5]. For this
purpose, argatroban and hirudin have been successfully used in
isolated patients undergoing peripheral vascular surgery and car-
diopulmonary bypass [6,7]. Danaparoid and lepirudin have also
been used in the setting of vascular surgery patients with alternate
success [4]. Nonetheless, intra and perioperative anticoagulation
in patients with known heparin induced thrombocytopenia, candi-
dates for vascular surgery, remains a challenge. Fondaparinux has
been used off-label in patients with HIT, despite a few reported, sus-
pect fondaparinux-induced HIT cases, and the consequent debate
on this off-label indication [8]. According to the SCARE criteria
[9], we report four consecutive patients with HIT, managed at an
Academic Hospital and one afﬁliated surgical center, undergoing
peripheral vascular surgery under fondaparinux for intra and peri-
operative anticoagulation, in order to evaluate its off-label use in
this special setting.
up Ltd. This is an open access article under the CC BY-NC-ND license (http://
 –  O
2 l of Su
2
y
v
u
b
u
b
p
2
t
w
a
a
(
s
b
d
E
o
f
t
t
O
w
o
r
F
t
o
a
d
d
2
w
f
4
a
s
a
n
a
t
w
a
d
r
w
i
i
c
m
t
u
d
wCASE  REPORT
52 G. Illuminati et al. / International Journa
. Presentation of cases
Four consecutive patients, of whom 3 men  of a mean age of 66
ears (range 52–74 years), with a known HIT, underwent 4 elective
ascular surgery operations under fondaparinux. The study and the
se of fondaparinux was approved by the institutional advisory
oard and the patients gave informed consent for both anticoag-
lant and surgical treatment. All the operations were performed
y the senior surgeons (GI, FGC). The essential clinical data of the
atients are resumed on Table 1.
.1. Patient # 1
A 74-year-old diabetic patient, 81 kg of body weight, was admit-
ed for the treatment of a critical lower limb ischemia associated
ith severe and extended aorto-ilio-femoral stenoses. At preoper-
tive coronary angiography, a critical stenosis of the right coronary
rtery was detected and treated with percutaneous intervention
PCI) consisting of stenting with a drug-eluting stent. Intravenous
odium heparin was administered during the procedure. Standard
lood tests the morning following PCI showed a platelet count
rop to 22 × 1000/dl. HIT was suspected and was conﬁrmed by
LISA test. The patient received dual antiplatelet therapy (100 mg
f oral aspirin + 75 mk  oral clopidogrel/day) and subcutaneous
ondaparinux 2.5 mg  every 12 h. This treatment was  continued
ill the evening before operation, resumed the same evening of
he operation and continued until discharge from the hospital.
peration was scheduled 5 days after PCI, when platelet count
as 73 × 1000/dl. Peripheral arterial revascularization consisted
f an axillo-biprofunda femoris bypass via a 8 mm polytetraﬂuo-
oethylene (PTFE) bypass (W.L. Gore and Associates, Flagstaff, Ariz).
or ﬂushing and tunneling, the graft was ﬁlled with saline solu-
ion. No signiﬁcant bleeding or arterial thrombosis of new onsed
ccurred intraoperatively. Postoperative course was uneventful
nd the patient was discharged home on postoperative day 6. Upon
ischarge fondaparinux administration was stopped, whereas the
ual antiplatelet treatment was maintained.
.2. Patient # 2
A 52-year-old woman, 59 kg of body weight, current smoker
ith a history of coronary artery disease (CAD), assuming war-
arin for atrial ﬁbrillation, was admitted for the treatment of a
.2 cm diameter aneurysm of the splenic artery. Two  days before
dmission warfarin was stopped and replaced with 6000 IU of
ubcutaneous enoxaparin twice a day. At preoperative coronary
ngiography a tight stenosis of the circumﬂex branch of left coro-
ary artery was detected and treated by PCI and implantation of
 drug-eluting stent. Intravenous sodium heparin was  adminis-
ered during the procedure. A drop of platelet count to 37 × 1000/dl
as observed at standard blood test the day after PCI and with
 diagnosis of suspect HIT, subsequently conﬁrmed at ELISA test,
ual antiplatelet treatment was continued and enoxaparin was
eplaced with 2.5 mg  of subcunaeous fondaparinux every 24 h. She
as scheduled to undergo open resection of the aneurysm, due to
ts aberrant origin from the superior mesenteric artery, as occurred
n a previously reported case [10], 8 days after PCI, with a platelet
ount of 88 × 1000/dl. Fondaparinux and dual antiplatelet treat-
ent were continued till the day before operation and resumedhe evening of operation itself. Intra and postoperative course was
neventful and the patient was discharged home on postoperative
ay 7, under dual antiplatelet therapy and fondaparinux. This latter
as replaced by warfarin two weeks after.PEN  ACCESS
rgery Case Reports 28 (2016) 251–254
2.3. Patient # 3
A 69-year-old diabetic man, 73 kg of body weight, was  admit-
ted for the treatment of a critical ischemia of the left lower limb
and received heparin administration for the treatment of arte-
rial disease. Two days after heparin administration his platelet
count dropped to 46 × 1000/dl, in the absence of any symptom of
thrombosis of new onset. HIT was  suspected and subsequently con-
ﬁrmed at ELISA test. He was  then administered 100 mg oral aspirin
and 2.5 mg  of fondaparinux subcutaneously twice a day. He was
scheduled for below-knee, femoropopliteal bypass with a reversed
saphenous vein graft, when platelet count reached 98000/dl 6 days
after, with aspirin and fondaparinux continued till the evening of
the operation and resumed the same evening of operation itself.
Tunnelling and ﬂushing of the graft was performed by ﬁlling it with
simple saline solution. Intra and postoperative course was unevent-
ful and the patient was discharged home on postoperative day 9,
under dual antiplatelet treatment. Fondaparinux was  stopped upon
discharge from the hospital.
2.4. Patient # 4
A 72-year-old man, 74 kg of body weight, with a history of CAD,
was admitted for the treatment of a popliteal artery aneurysm.
At preoperative coronary angiography a signiﬁcant stenosis of the
right coronary artery was detected and treated by PCI, with deploy-
ment of two drug-eluting stents. Heparin was  administered during
the procedure and platelet count the day after PCI dropped to
42 × 1000/dl, without any apparent symptom of arterial or venous
thrombosis. The patient was  kept under dual antiplatelet treat-
ment, and scheduled for aneurysm resection 5 days later, when
platelet count was 110 × 1000/dl. Dual antiplatelet treatment was
continued till the evening before operation and resumed the same
night of operation itself. The morning of operation he was admin-
istered 2.5 mg  of fondaparinux subcutaneously and subsequently
underwent aneurysm resection/reversed saphenous vein grafting.
Fondaparinux was  resumed six hours after the end of operation and
continued twice a day (2.5 mg/12 h), together with dual antiplatelet
treatment unitl discharge from the hospital, on post-operative day
7, after an uneventful course.
3. Discussion
The results of this study seem to show that the off-label use
of fondaparinux for intra and perioperative anticoagulation, in
patients with HIT, candidates for peripheral vascular surgery is
both safe and effective. The management of patients with HIT
remains challenging and an optimal, alternative anticoagulation
has not been established yet [5]. This is especially true in patients
candidates for cardiac and vascular surgery [11]. As an alterna-
tive, argatroban [6], hirudin [7], lepirudin [12] have been used,
with alternate results, as bleeding requiring reoperation or allo-
genic transfusions have also been observed [6,13]. Off-label use of
fondaparinux in case of suspected HIT has already been reported
[14]. In this case series we studied a further off-label use of fon-
daparinux, which is intra and perioperative anticoagulation in
peripheral vascular surgery. The preliminary results seem to be
encouraging, as two axillo-bifemoral, one femoro-popliteal and one
splenic artery aneurysm resection could be safely performed with-
out either thromboembolic or bleeding episodes. In the present
study fondaparinux could be administered subcutaneously through
the intra and perioperative period, at regular, standard doses, with-
out requiring either intraoperative infusion or monitoring of the
coagulation. Tunnelling of the grafts, which is usually performed
under tension and previous ﬁlling of the graft with heparinized
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Table  1
Essential clinical data of the patients’ series. HIT, Heparin Induced Thrombocytopenia; CAD, Coronary Artery Disease; ASA, aspirin; GSV Greater Saphenous Vein.
Pt  Sex Age
(years)
Body
weight (Kg)
Comorbidities Arterial disease HIT-Triggering
circumstance
Fondaparinux
Dosage
Associated
antiplatelet dosage
Intervention
1 M 74 81 Diabetes, CAD Critical limb
ischemia
Coronary
angiography and
stenting
5  mg/24 h ASA + Clopidogrel Axillo-bifemoral
bypass
2  F 52 59 CAD, atrial
ﬁbrillation
Splenic artery
aneurysm
Coronary
angiography and
stenting
2,5 mg/24 h ASA + Clopidogrel Aneurysm
resection
3  M 69 73 Diabetes, CAD Critical limb
ischemia
Heparin
administration for
ischemia
5 mg/24 h ASA Below-knee
femoro-popliteal
by pass (reversed
GSV)
4  M 72 74 CAD Popliteal artery
aneurysm
Coronary
angiography and
stenti
5  mg/24 h ASA + Clopidogrel Resection/Reversed
GSV grafting
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[olution, could be successfully performed after ﬁlling with sim-
le saline. This is a fairly crucial point as tunneling of the graft
nder tension is especially important for infragenicular bypasses
erformed for critical ischemia or diabetic foot, in order to avoid
inking or twisting of the graft, which would cause graft thrombo-
is [15]. Simple saline was also used for irrigation of the graft and
un-off vessels. Simplicity of use and reliability of fondaparinux
as apparent in all the reported cases. Nonetheless, as suspect,
ondaparinux-induced HIT cases have been reported [8,14,16–19],
ts systematic use in patients with HIT, candidates for peripheral
ascular interventions should still be done with caution. Beside
he limitations of any small patients’ cohort, this study has the
isadvantage of dealing with axillo-femoral and femoro-popliteal
ypasses or splenic artery aneurysm resection, thus not testing fon-
aparinux in the setting of aortic surgery, which is expected to
e associated with a higher bleeding risk than the former oper-
tions. Although aortic and digestive arteries surgery under dual
ntiplatelet treatment has been reported [20,21], large experience
ith the combination of dual antiplatelet treatment and fonda-
arinux in this setting is lacking. Apart such limitations, the results
f this study support the off-label use of fondaparinux for periph-
ral vascular surgery in patients with HIT. Hopefully further studies
ased on larger number of patients will conﬁrm and validate these
reliminary results.
. Conclusion
The present report adds to the existing literature the infor-
ation that fondaparinux seems safe and effective, for intra and
erioperative anticoagulation, in patients with HIT, candidates for
eripheral vascular surgery. It may  deserve consideration for stan-
ard use in this special clinical setting.
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